Search
Search
Daniel F. Kiernan, MD, FACS; Prethy Rao, MD, MPH, FACS; Andrew M. Schimel, MD
Show Description +
What are the findings from the phase 3 PULSAR study, which assessed EYLEA HD for the treatment of Neovascular (Wet) Age-Related Macular Degeneration (AMD)? Moderator Daniel F. Kiernan, MD, FACS, and panelists Prethy Rao, MD, MPH, FACS, and Andrew M. Schimel, MD, explore the safety and efficacy outcomes from PULSAR and dive into nuances of the study's findings.
Posted: 3/13/2025
Daniel F. Kiernan, MD, FACS; Prethy Rao, MD, MPH, FACS; Andrew M. Schimel, MD
What are the findings from the phase 3 PULSAR study, which assessed EYLEA HD for the treatment of Neovascular (Wet) Age-Related Macular Degeneration (AMD)? Moderator Daniel F. Kiernan, MD, FACS, and panelists Prethy Rao, MD, MPH, FACS, and Andrew M. Schimel, MD, explore the safety and efficacy outcomes from PULSAR and dive into nuances of the study's findings.
Posted: 3/13/2025
Assessing Treatment Paradigms in Wet AMD and DME Therapy in the Age of Extended Dosing Intervals: Parts 1 and 2
Assessing Treatment Paradigms in Wet AMD and DME Therapy in the Age of Extended Dosing Intervals: Part 3
About Regeneron
Regeneron is a leading biotechnology company that invents, develops, and commercializes life-transforming medicines for people with serious diseases. Founded and led for nearly 35 years by physician-scientists, Regeneron's unique ability to repeatedly and consistently translate science into medicine has led to numerous FDA-approved treatments and product candidates in development, almost all of which were homegrown in Regeneron's laboratories.
Visit us online: regeneron.com
Follow Regeneron
EYLEA HD is a registered trademark of Regeneron Pharmaceuticals, Inc.
© 2025 Regeneron Pharmaceuticals, Inc. All rights reserved.
03/2025
US.EHD.25.02.0123
